Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Gilead Sciences will pay Nurix Therapeutics $45 million up front to collaborate on targeted protein degradation therapies for cancer and other diseases. Whereas conventional small-molecule drugs block the function of a protein, Nurix’s compounds can break down the protein altogether. The biotech firm’s technology harnesses enzymes called E3 ligases that dictate when a protein gets broken down in the cell. Under the multiyear pact, Gilead can license drug candidates against five undisclosed protein targets.
This article has been sent to the following recipient: